Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for the month of March 2020. The filing identifies I-MAB’s principal executive offices in Shanghai, China, and states that the company files annual reports on Form 20-F. The filing is dated March 30, 2020.
Financial Information
The filing text provided consists only of the Form 6-K cover page and an exhibit index. It does not provide revenue, profit, cash flow, margins, debt, liquidity, operating metrics, or other financial results.
Material Changes and Outlook
No material changes, guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided filing text.
Exhibits and Filing Details
- Exhibit 99.1 is identified as a press release, but its contents are not included in the provided text.
- The filing was signed by Jielun Zhu, Director and Chief Financial Officer.
- The filing’s identified registrant is I-MAB, which differs from the company name in the request metadata, “Novabridge Biosciences.”
Investor Verification Points
- Verify the registrant identity and confirm whether I-MAB is the intended company.
- Obtain and review Exhibit 99.1, the referenced press release.
- Confirm whether the missing exhibit contains financial results, clinical developments, financing information, or other material disclosures.